Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus CHILDREN S ALLEGRA HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus CHILDREN S ALLEGRA HIVES.
BENADRYL vs CHILDREN'S ALLEGRA HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Category C
Category C
Antihistamine
Antihistamine